pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip
Phase 1 · other · Glioma
Vemurafenib (ZELBORAF) is an oral antineoplastic agent being evaluated in the ReDiReCCT (Repurposed Drugs in Research and Cancer Clinical Trials) trial for glioma treatment. Originally approved as a BRAF inhibitor for melanoma, this program represents a drug repurposing strategy sponsored by Disc Medicine to explore ve
Internal code 14341
Vemurafenib (ZELBORAF) is an oral antineoplastic agent being evaluated in the ReDiReCCT (Repurposed Drugs in Research and Cancer Clinical Trials) trial for glioma treatment. Originally approved as a BRAF inhibitor for melanoma, this program represents a drug repurposing strategy sponsored by Disc Medicine to explore vemurafenib's efficacy in glioma, a distinct oncology indication. The trial is currently in Phase 1 and remains active. Vemurafenib is already approved in multiple jurisdictions: the United States (FDA, NDA 202429), European Union (EMA authorization 19/06/2025), and Australia (TGA, listed 01/04/2017). The repurposing approach leverages an established safety and pharmacology profile to accelerate clinical evaluation in a new indication. No mechanism of action, specific target, or lead investigator details have been disclosed for this glioma program. Key regulatory milestones and expected next clinical progression dates remain not yet disclosed.
Glioma represents a significant unmet medical need with limited treatment options and poor prognosis, particularly for high-grade tumors. Drug repurposing strategies offer potential advantages by reducing development timelines and costs compared to de novo drug discovery, while leveraging established safety databases. Vemurafenib's mechanism as a BRAF inhibitor may have relevance in glioma subtypes harboring BRAF mutations, though this has not been explicitly confirmed in the disclosed facts. The ReDiReCCT trial's Phase 1 status indicates early-stage evaluation of tolerability and preliminary efficacy signals in this new indication.
From a competitive standpoint, the glioma market includes multiple approved antineoplastic agents (AFINITOR, OFEV, KYPROLIS, and others listed in the competitive landscape), though these represent different mechanisms and indications. The repurposing of an already-approved drug may offer regulatory and commercial advantages if efficacy is demonstrated, potentially enabling faster market access than novel agents. Patient populations with glioma, particularly those with BRAF-mutant tumors, represent a defined but limited market segment. Commercial significance depends on trial outcomes, regulatory decisions, and differentiation from existing glioma therapies.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Modality: Small molecule (oral)
Route of Administration: Oral
Brand Name: ZELBORAF
International Nonproprietary Name (INN): Vemurafenib
Mechanism of Action: Not disclosed for this glioma program; however, vemurafenib is established as a BRAF kinase inhibitor approved for melanoma.
Target: Not disclosed for this glioma program.
Related Therapies: Other approved antineoplastic agents in the competitive landscape include IMBRUVICA (Janssen-Cilag), AFINITOR (Novartis), KYPROLIS (Amgen), INLYTA (Pfizer), and OFEV (Boehringer Ingelheim).
First Approval: Vemurafenib was approved in Australia on 01/04/2017 and in the European Union on 19/06/2025; U.S. approval via NDA 202429 (date not specified in facts).
Patent Status: Not disclosed.
Also known as: glial neoplasm, glial tumor, glial tumour, neoplasm of neuroglia, neoplasm of the neuroglia, neuroglial neoplasm
Prevalence: Point prevalence: 1-5 / 10 000 (Europe) — source: Orphanet, validated.
A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.
ClinicalTrials.gov lists 517 registered studies for Glioma (AACT aggregate).
Phase breakdown: NA (265), PHASE1 (85), PHASE2 (82), PHASE1/PHASE2 (33), EARLY_PHASE1 (29), PHASE3 (13), PHASE2/PHASE3 (7), PHASE4 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0021042), Orphanet — glioma, NCT00001150, NCT00001336, NCT00001341, NCT00001444, NCT00001500, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, NCT00001148, NCT00001171, NCT00001502, NCT00001573, NCT00009035, Open Targets Platform (CC BY 4.0).
ReDiReCCT Trial Phase 1 Active
Vemurafenib Phase 1 trial for glioma ongoing; no enrollment completion or progression dates disclosed.
The glioma treatment landscape includes multiple approved antineoplastic agents across different mechanisms and indications. Competitors identified in the facts include AFINITOR (Novartis), KYPROLIS (Amgen), IMBRUVICA (Janssen-Cilag), INLYTA (Pfizer), OFEV (Boehringer Ingelheim), LYSODREN, LYNOZYFIC (Regeneron), VYXEOS LIPOSOMAL (Jazz Pharmaceuticals), UNITUXIN (United Therapeutics), PACLITAXEL ACCORD (Accord Healthcare), and ARX-IMATINIB (Alphapharm). Most are approved in Australia and/or other major markets. Vemurafenib's competitive positioning as a repurposed BRAF inhibitor in glioma remains unclear pending Phase 1 data; differentiation would depend on efficacy, safety, and patient selection (e.g., BRAF-mutant tumors). The established approval status and known safety profile of vemurafenib may offer advantages over novel agents, but clinical efficacy in glioma has not yet been demonstrated in the disclosed facts.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| UNITUXIN | United Therapeutics Europe Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| EVEROLIMUS | — | FK506-binding protein 1A inhibitor | Approved |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| VINCRISTINE SULFATE | — | Tubulin inhibitor | Phase 3 |
| VINCRISTINE | — | Tubulin inhibitor | Phase 3 |
| TRANEXAMIC ACID | — | Plasminogen inhibitor | Phase 3 |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOVORAFENIB | — | RAF serine/threonine protein kinase inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Vemurafenib approved via NDA 202429; sponsor Hoffmann La Roche. Specific approval date not disclosed.
European Union (EMA): Vemurafenib (ZELBORAF) authorized 19/06/2025; Marketing Authorization Holder: Roche Registration GmbH; EMA Product Number EMEA/H/C/002409.
Australia (TGA): Vemurafenib listed 01/04/2017; PBS codes 11076Y and 11081F; sponsor Roche Products Pty Ltd.
China (NMPA): Vemurafenib in clinical trials; NCT04423185 registered for China.
Japan (PMDA): Regulatory status not disclosed.
ReDiReCCT Trial (Glioma Indication): Phase 1 status; sponsor Disc Medicine; NCT ID 2025-523340-12-00. No regulatory milestones, expected approval timelines, or label expansion plans disclosed.
Vemurafenib (ZELBORAF) is an approved antineoplastic agent. It is currently being evaluated in the ReDiReCCT Phase 1 trial for glioma treatment; its established indication is melanoma.
Yes, vemurafenib is FDA-approved via NDA 202429 under sponsor Hoffmann La Roche; the specific approval date is not disclosed in the facts.
Yes, vemurafenib (ZELBORAF) received EMA authorization on 19/06/2025; Marketing Authorization Holder is Roche Registration GmbH (EMEA/H/C/002409).
Yes, vemurafenib was listed on the Australian Register of Therapeutic Goods on 01/04/2017 by Roche Products Pty Ltd (PBS codes 11076Y and 11081F).
ReDiReCCT (Repurposed Drugs in Research and Cancer Clinical Trials) is a Phase 1 trial sponsored by Disc Medicine evaluating vemurafenib in glioma; it is currently active (NCT ID 2025-523340-12-00).
Disc Medicine is the sponsor of the ReDiReCCT trial evaluating vemurafenib in glioma.
Vemurafenib is a BRAF kinase inhibitor; however, the specific mechanism of action for the glioma indication has not been disclosed.
Vemurafenib is administered orally as a tablet.
Vemurafenib for glioma is in Phase 1 development and currently active; no progression to Phase 2 has been disclosed.
Vemurafenib is classified as an antineoplastic and immunomodulating agent (ATC L01).
Roche manufactures vemurafenib; regulatory approvals list Hoffmann La Roche (FDA), Roche Registration GmbH (EMA), and Roche Products Pty Ltd (Australia) as sponsors/MAHs.
Yes; approved competitors include AFINITOR (Novartis), KYPROLIS (Amgen), IMBRUVICA (Janssen-Cilag), INLYTA (Pfizer), OFEV (Boehringer Ingelheim), and others listed in the competitive landscape.
The indication is glioma; vemurafenib is being evaluated as a repurposed drug for this oncology indication.
Clinical trial results for vemurafenib in glioma have not yet been reported; the Phase 1 trial is ongoing.
Expected milestones and completion dates for the ReDiReCCT trial have not been disclosed.
Yes; vemurafenib is listed as in clinical trials in China (NCT04423185), though this may refer to a different indication than glioma.
14341 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Disc Medicine's sponsorship of the ReDiReCCT trial represents a drug repurposing strategy to extend vemurafenib's clinical utility beyond melanoma. This approach may reduce development risk and timelines compared to novel agents, leveraging an established safety and pharmacology database. Success in glioma could support label expansion and market differentiation.
Competitive Implications: If Phase 1 data support progression, vemurafenib would compete in a crowded glioma market with multiple approved antineoplastic agents. Differentiation would likely depend on efficacy in BRAF-mutant glioma subtypes and favorable tolerability. The repurposed status offers no inherent competitive advantage over mechanism-specific competitors unless clinical outcomes are superior.
Future Catalysts: Phase 1 data readout and decision to advance to Phase 2; potential biomarker-driven patient selection (BRAF mutation status); regulatory feedback on indication strategy; competitive trial data from other glioma agents.
Expected Milestones: Phase 1 completion and safety/efficacy summary; Phase 2 initiation (if warranted); regulatory interactions with FDA/EMA on development pathway; potential label expansion if approved.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.